---
layout: minimal-medicine
nav_exclude: true
title: Trastuzumab
---

# Trastuzumab

**Generic Name:** Trastuzumab-dkst, Trastuzumab-anns, Trastuzumab-qyyp (Several biosimilars exist with slightly different names)  Note:  "Trastuzumab" itself refers to the brand name Herceptin,  the biosimilars are named slightly differently.

**Usage:**  Trastuzumab biosimilars are used to treat HER2-positive breast cancer.  This means they are used in patients whose cancer cells have an excess of the HER2 protein.  They may be used:

* **Adjuvant setting:** After surgery, to reduce the risk of the cancer returning.
* **Neoadjuvant setting:** Before surgery, to shrink the tumor.
* **Metastatic setting:** To treat cancer that has spread to other parts of the body.
* **In combination with other therapies:** Trastuzumab is often used with chemotherapy, other targeted therapies, or hormone therapy.

The specific use and dosage will depend on the individual patient and their cancer's characteristics, determined by the oncologist.


**Side Effects:**  Like all medications, trastuzumab biosimilars can cause side effects.  Some common side effects include:

* **Heart problems:** Cardiomyopathy (weakening of the heart muscle) is a serious potential side effect.  Regular heart function monitoring is essential.
* **Infusion reactions:**  These can range from mild (flushing, chills, fever) to severe (anaphylaxis).  Pre-medication is often given to reduce this risk.
* **Nausea and vomiting:**  Common side effects, often manageable with anti-nausea medication.
* **Diarrhea:**  Can be mild to moderate.
* **Fatigue:**  A common side effect of cancer treatment.
* **Headache:**  Can occur.
* **Low blood counts:** (Neutropenia, thrombocytopenia, anemia)  Increasing risk of infection or bleeding.
* **Lung problems:**  (Interstitial lung disease) a rare but serious side effect requiring immediate medical attention.
* **Liver problems:**  Elevated liver enzymes.

This is not an exhaustive list, and the severity and frequency of side effects vary greatly between individuals.


**How it Works:** Trastuzumab is a monoclonal antibody.  It targets the HER2 protein found on the surface of some breast cancer cells. By binding to HER2, trastuzumab blocks the HER2 signaling pathways, which are crucial for cancer cell growth and division. This ultimately inhibits the growth and spread of HER2-positive breast cancer cells.


**FAQs:**

* **Are trastuzumab biosimilars as effective as Herceptin?**  Extensive studies have shown that trastuzumab biosimilars are highly similar to Herceptin in terms of efficacy and safety.  Regulatory approval requires demonstrating biosimilarity.
* **Are there any differences between different trastuzumab biosimilars?** While highly similar, subtle differences may exist between various biosimilars in terms of manufacturing processes and minor variations in the drug molecule. These differences are generally not clinically significant.
* **How is trastuzumab administered?** It's given intravenously (IV) through an infusion, usually over 30-90 minutes.
* **How long is the treatment course?** The duration of treatment varies depending on the stage of cancer and the treatment regimen. It can range from several months to years.
* **What should I do if I experience side effects?**  Report any side effects to your doctor immediately.  They can adjust your treatment or provide supportive care to manage your symptoms.


**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  They can provide personalized guidance based on your specific situation.


**Note:** This information is AI-generated or crowd-sourced and may not be accurate. Please consult a medical professional for verified advice.